Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR p.T790M status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized osimertinib for treatment of adult patients with locally advanced or metastatic EGFR p.T790M mutation-positive non-small cell lung cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
TAGRISSO as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.